BR112015015870A8 - composição farmacêutica, e, uso de uma composição farmacêutica - Google Patents

composição farmacêutica, e, uso de uma composição farmacêutica

Info

Publication number
BR112015015870A8
BR112015015870A8 BR112015015870A BR112015015870A BR112015015870A8 BR 112015015870 A8 BR112015015870 A8 BR 112015015870A8 BR 112015015870 A BR112015015870 A BR 112015015870A BR 112015015870 A BR112015015870 A BR 112015015870A BR 112015015870 A8 BR112015015870 A8 BR 112015015870A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical compositions
methods
pharmaceutical
abstract
Prior art date
Application number
BR112015015870A
Other languages
English (en)
Other versions
BR112015015870A2 (pt
BR112015015870B1 (pt
Inventor
Alan Stoloff Gregory
Brew John
Pleguezuelos Mateo Olga
Mark Bannister Robin
Jane Dilly Suzanne
Caparrós-Wanderley Wilson
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Publication of BR112015015870A2 publication Critical patent/BR112015015870A2/pt
Publication of BR112015015870A8 publication Critical patent/BR112015015870A8/pt
Publication of BR112015015870B1 publication Critical patent/BR112015015870B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica” a presente descriã§ã£o descreve composiã§ãµes farmacãªuticas, mã©todos de preparaã§ã£o de tais composiã§ãµes farmacãªuticas, e mã©todos e usos do tratamento de uma inflamaã§ã£o crã³nica e/ou doenã§a inflamatã³ria em um indivã­duo utilizando tais composiã§ãµes farmacãªuticas.
BR112015015870-6A 2013-02-04 2014-01-14 Uso de uma composição farmacêutica BR112015015870B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752309P 2013-02-04 2013-02-04
US61/752,309 2013-02-04
PCT/EP2014/050627 WO2014117999A1 (en) 2013-02-04 2014-01-14 Compositions and methods for treating chronic inflammation and inflammatory diseases

Publications (3)

Publication Number Publication Date
BR112015015870A2 BR112015015870A2 (pt) 2017-07-11
BR112015015870A8 true BR112015015870A8 (pt) 2018-01-16
BR112015015870B1 BR112015015870B1 (pt) 2022-09-27

Family

ID=50150686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015870-6A BR112015015870B1 (pt) 2013-02-04 2014-01-14 Uso de uma composição farmacêutica

Country Status (14)

Country Link
EP (1) EP2950821A1 (pt)
JP (1) JP6474352B2 (pt)
KR (1) KR20150129664A (pt)
CN (1) CN105120900A (pt)
AU (1) AU2014211715B2 (pt)
BR (1) BR112015015870B1 (pt)
CA (1) CA2898017A1 (pt)
HK (1) HK1218621A1 (pt)
IL (1) IL239920A0 (pt)
MX (1) MX366317B (pt)
RU (1) RU2680801C2 (pt)
SG (1) SG11201505243PA (pt)
WO (1) WO2014117999A1 (pt)
ZA (1) ZA201505006B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
WO2017004142A1 (en) 2015-06-29 2017-01-05 Children's Medical Center Corporation Treatment for myopathy
CN108283637A (zh) * 2018-04-04 2018-07-17 无锡市儿童医院 辛伐他汀的应用
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use
EP3976072A4 (en) * 2019-06-03 2023-03-29 Immunolux International Corp. SMALLPOX VACCINE AND STEM CELLS FOR THE TREATMENT OF DISEASE
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2752764C1 (ru) * 2020-12-14 2021-08-03 Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") Фармацевтическая композиция, обладающая противовоспалительным действием
RU2760220C1 (ru) * 2021-06-02 2021-11-22 Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Способ определения клинически значимой усталости у больного ревматоидным артритом на фоне 5-летней терапии базисными противовоспалительными препаратами или базисными противовоспалительными препаратами в комплексе с генно-инженерными биологическими препаратами и/или психофармакотерапией и сопутствующего расстройства тревожно-депрессивного спектра

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
PL191780B1 (pl) * 1997-07-29 2006-07-31 Upjohn Co Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
JP2002544155A (ja) * 1999-05-07 2002-12-24 ファルマソル ゲーエムベーハー 流体および固体脂質の混合物を基礎とする脂質粒子、およびそれらを製造するための方法
PT1183014E (pt) * 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
AU2004258745A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
CA2607738A1 (en) * 2005-04-28 2006-11-02 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
US20070249725A1 (en) * 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
JP2014504629A (ja) * 2011-02-04 2014-02-24 バイオコピア リミテッド 慢性炎症および炎症性疾患を治療するための組成物および方法

Also Published As

Publication number Publication date
IL239920A0 (en) 2015-08-31
MX2015009058A (es) 2016-01-08
CN105120900A (zh) 2015-12-02
MX366317B (es) 2019-07-03
JP2016506941A (ja) 2016-03-07
RU2015137659A (ru) 2017-03-10
CA2898017A1 (en) 2014-08-07
ZA201505006B (en) 2016-03-30
RU2680801C2 (ru) 2019-02-27
BR112015015870A2 (pt) 2017-07-11
SG11201505243PA (en) 2015-08-28
JP6474352B2 (ja) 2019-02-27
AU2014211715A1 (en) 2015-07-23
EP2950821A1 (en) 2015-12-09
AU2014211715B2 (en) 2016-08-25
KR20150129664A (ko) 2015-11-20
HK1218621A1 (zh) 2017-03-03
WO2014117999A1 (en) 2014-08-07
BR112015015870B1 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2018007871A (es) Composiciones para el cuidado personal.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
BR112014030570A2 (pt) extratos de tomilho selvagem e uso destes
EA201690574A1 (ru) Применение пидотимода в лечении заболеваний, связанных с воспалением
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2014, OBSERVADAS AS CONDICOES LEGAIS